| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/JAMA.282.8.786 |
| P698 | PubMed publication ID | 10463718 |
| P50 | author | Bruce M. Psaty | Q30429993 |
| Susan R Heckbert | Q88077554 | ||
| P2093 | author name string | T D Koepsell | |
| D Lin | |||
| D S Siscovick | |||
| F R Rosendaal | |||
| T R Fleming | |||
| N L Smith | |||
| C D Furberg | |||
| N S Weiss | |||
| E H Wagner | |||
| R C Kaplan | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| drug approval | Q42214612 | ||
| P1104 | number of pages | 5 | |
| P304 | page(s) | 786-790 | |
| P577 | publication date | 1999-08-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease | |
| P478 | volume | 282 |
| Q34236623 | Angiotensin-converting enzyme inhibitors |
| Q37117293 | Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis |
| Q24805075 | Back to thiazide-diuretics for hypertension: reflections after a decade of irrational prescribing |
| Q36381197 | Bayesian methods for evidence synthesis in cost-effectiveness analysis |
| Q33756518 | Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma |
| Q35912696 | Biomarkers and surrogate endpoints in glaucoma clinical trials |
| Q34107924 | Biomarkers as surrogates for cancer development |
| Q54629860 | Biomarkers: stepping stones to firmer end points. |
| Q42763911 | British guidelines on managing hypertension. Provide evidence, progress, and an occasional missed opportunity |
| Q24187385 | Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients |
| Q24244091 | Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients |
| Q36599365 | Clinical trial design issues: at least 10 things you should look for in clinical trials |
| Q36896973 | Clinical trials and tribulations--lessons from pulmonary fibrosis |
| Q34076188 | Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents |
| Q36137741 | Cost-effectiveness of blood glucose test strips in the management of adult patients with diabetes mellitus. |
| Q24792307 | Current Controlled Trials: an opportunity to help improve the quality of clinical research |
| Q24792578 | Debate: The slippery slope of surrogate outcomes |
| Q50146983 | Developing a Clinician Friendly Tool to Identify Useful Clinical Practice Guidelines: G-TRUST. |
| Q36020575 | Do firms underinvest in long-term research? Evidence from cancer clinical trials |
| Q33703000 | Drug therapies for the primary prevention of cardiovascular events: trials and errors: 2009 Ancel Keys Memorial Lecture |
| Q28550578 | Drug-Gene Interactions of Antihypertensive Medications and Risk of Incident Cardiovascular Disease: A Pharmacogenomics Study from the CHARGE Consortium |
| Q29247935 | Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: protocol for an overview of systematic reviews |
| Q28307968 | Effectiveness of general practice-based health checks: a systematic review and meta-analysis |
| Q33725286 | Enhancing prescription drug innovation and adoption |
| Q42345806 | Evidence-based medicine: worship of form and treatment of high blood pressure |
| Q34090645 | First line drugs in chronic stable effort angina--the case for newer, longer-acting calcium channel blocking agents |
| Q32066328 | Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus |
| Q24244250 | Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease |
| Q50117601 | In pursuit of truth: A critical examination of meta-analyses of cognitive behavior therapy |
| Q45342248 | Incretins and pancreatitis--what happens next? A personal viewpoint |
| Q53320580 | Independent clinical research in Europe. |
| Q36088088 | Institutional conflicts of interest: protecting human subjects, scientific integrity, and institutional accountability |
| Q35582653 | Interpretation of observational studies |
| Q36103356 | Is suicide ideation a surrogate endpoint for geriatric suicide? |
| Q37993151 | Looking ahead: clinical trial design in adult congenital heart disease |
| Q37057982 | Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. |
| Q24626999 | Marital quality and health: a meta-analytic review |
| Q79181244 | Mechanism of an Inhibitory Effect of nipradilol on Rat Vascular Smooth Muscle Cell Growth |
| Q37458317 | Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. |
| Q24187392 | Metformin monotherapy for type 2 diabetes mellitus |
| Q24246552 | Metformin monotherapy for type 2 diabetes mellitus |
| Q51765129 | Methylomic survival predictors, frailty, and mortality. |
| Q36320595 | Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials |
| Q45329433 | Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy |
| Q38599879 | MortalityPredictors.org: a manually-curated database of published biomarkers of human all-cause mortality |
| Q28578027 | Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2 |
| Q37282191 | Observational research--opportunities and limitations |
| Q36089528 | Pharmacogenetics of response to statins: where do we stand? |
| Q35000520 | Portfolio of clinical research in adult cardiovascular disease as reflected in ClinicalTrials.gov |
| Q34009185 | Primary cancer prevention trials |
| Q53476526 | Result-based compensation in health care: a good, but limited, idea. |
| Q37877123 | Rosiglitazone and the risk of adverse cardiovascular outcomes. |
| Q34274534 | Salt and blood pressure. Conventional wisdom reconsidered |
| Q48556367 | Straight talk from... Bruce Psaty. Interviewed by Emma Marris |
| Q64095009 | Study of Frontal Alpha Asymmetry in Mild Depression: A Potential Biomarker or Not? |
| Q44140689 | Surrogate end points as a clinical and public health problem. The cerivastatin case |
| Q34564309 | Surrogate end points in heart failure |
| Q37556678 | Surrogate outcomes in health technology assessment: an international comparison |
| Q59329222 | The Failure to Measure Dietary Intake Engendered a Fictional Discourse on Diet-Disease Relations |
| Q24810516 | The benefits and threats of research partnerships with industry |
| Q35058214 | The challenges of conducting clinical endpoint studies |
| Q36740585 | The risky reliance on small surrogate endpoint studies when planning a large prevention trial |
| Q37035523 | The role of surrogate endpoints in the evaluation of efficacy and safety of therapeutic interventions in diabetes mellitus |
| Q28543430 | The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders |
| Q24793926 | The usefulness of information on HDL-cholesterol: potential pitfalls of conventional assumptions |
| Q37385281 | Tracking biocultural pathways in population health: the value of biomarkers |
| Q35686511 | Traditional and novel risk factors in older adults: cardiovascular risk assessment late in life |
| Q35128447 | Trends in clinical trials in surgical oncology: Implications for outcomes research |
| Q36267738 | Validation of self-reported periodontal disease: a systematic review |
| Q30558549 | Validity and reliability of electroencephalographic frontal alpha asymmetry and frontal midline theta as biomarkers for depression |
| Q36022784 | Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? |
Search more.